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832-5 Catheter-Based Brachytherapy for Aorto-Ostial In-Stent 
Restenosis 
MChran Moussavian, Manuela Negotia, Jeffrey W. Moses, Martin B. Leon, Roxanna 
Mehran, John P, Reilly, Mark A. Gdse, Paul S, Teirstein, Scripps Clinic, La Jolla, 
Califomia. 
Background: Although aorto-ostial lesions have been included in previous radiation trials, 
the impact of brachytherapy in this patient subset at high dsk for restenosis is unknown. 
Therefore, we examined the efficacy of iddium-192 for ecrto-ostial in-stent restenosis, 
Methods: Of 252 patients from Scdpps Clinic enrolled in the SCRIPPS III trial, 27 patients 
had aorto-ostial in-stent restenosis, defined as lesion location within 3 mm of the ostial 
saphenous vein graft (SVG), left main coronary artery (LMCA), right coronary artery 
(RCA) or the left internal mammary artery (LIMA). Patients were treated with balloon 
angioplasty, atherectomy, or stant deployment followed by iridium-192 brachytherapy. 
Results: The mean follow-up duration is 337 days, Clinical outcome, death, MI, and need 
for TLR were obtained. Ostial RCA lesions were present in 14 patients (51%), ostial SVG 
in 7 (26%), ostial LMCA in 5 (18%), and LiMA in 1 (4%). All patients underwent balloon 
angioplasty (100%), 5 (17%) had rotational atherectomy, and 7 (26%) had stent deploy- 
ment. Treatment length was >55 mm in 12 patients (44%). Seven patients (26%) 
required subsequent TLR. There was one non-cardiac death. TLR was more frequent in 
patients requidng stent deployment at the time of brachytherapy (57% vs. 15%, 
p=0,049), and in patients with a treatment length >55 mm (50% vs. 6.7%, p=0.02). TLR 
was similar for all lesion locations (28.6% ostial RCA, 25% ostial SVG, 20% LMCA, 
p=0.81). 
Conclusions: Brachytherepy using gamma emitters appears to be an effective therapy for 
treatment of aorto-ostial in-stent restenosis, especially in patients who do not receive a 
new stent dudng the radiation procedure and patients who have short ostial lesions. 
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832-6 Intrscoronary Gamma Radiation for In-Stent Reetenosis 
in Saphenous Vein Grafts Versus Native Coronaries 
Andrew E. Aiani. Ron Waksman, Edouard Cheneau, Dong-Hun Cha, Hamid Yazdi, 
Afework Gebreeyesus, Veronica Reed, Ellen Pinnow, Lowell F, Saber, Augusto D. 
Pichard, Kenneth M. Kent, Joseph Undsey, Washington Hospital Center, Washington, 
DisL of Columbia. 
Background: Intracoronary radiation therapy (IRT) is effective in reducing recurrence of 
in-stent restenosis (ISR) in native coronary artedes. This study compares the effective- 
ness and safety of IRT using gamma radiation for the treatment of ISR in saphenous vein 
grafts (SVG) versus native coronaries. Methods: In the WRIST (Washington Radiation 
for In-Stent restenosis Trial) series of gamma radiation tdals, 1142 patients were enrolled 
(912 in native coronaries and 230 in SVG) and completed 6 months clinical and anglo- 
graphic follow-up. All patients (pts) underwent PTCA, atherectomy, and/or additional 
stents, Different dbbon lengths containing 6-23 seeds of 192-1r or non-radioactive seeds 
were used to cover lesion lengths <80 mm (mean radiation length of 55±14 ram). The 
prescribed radiation doses were 14 or 15 Gy to 2 mm radial distance from the center of 
the source. Results: Baseline demographic, angiographic and procedural details were 
similar, except SVG pts were older (65±13 vs. 61±11yrs, p<0.001), more likely male 
(80% vs. 64%, p<0.001), had more multi-vessel disease (81% vs. 50%, p<0.001) and 
less diffuse lesions (17¢10 vs. 24±12mm, p<0.O01). Treatment of ISR with gamma radia- 
tion in SVG's had similar outcomes to native coronades (Table). Conclusions: Based on 
this compadson, the use of gamma radiation for the treatment of ISR should be 
expanded to SVG's, 
SVG Native coronaries P 
(N=230) (N=912) 
Death, % 2.4 2.6 0.80 
Q-wave MI, % 1.0 1.3 0.77 
TLR, % 17.2 14.2 0.29 
TVR, % 27.1 23.4 0.23 
Late Thrombosis, % 2.1 2.7 0.62 
MACE (TLR), % 18.2 15.5 0.35 
Angiogrephic Restenosis (>50°/o), % 21.7 28.6 0.27 
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844-I Outcomes In Dlabetic Petlents Undergolng 
Percutaneous Coronary Interventlon: A Report From 
the NHLBI Dynamic Registry 
Warren K. Laskev. Faith Selser, Janet M. Johnston, Helen O. Vlachos, Alice Jacobs, 
David R. Holmes, John Douglas, Spencer B. King, III, Peter C. Block, Robert Wilensky, 
David O. Williams, Katherine Detre, University of Maryland, Baltimore, Maryland, 
University of Pittsburgh, Pittsburgh, Pennsylvania. 
Background: Historically, diabetic patients appear to be at increased dsk for adverse 
outcomes following percutaneous coronary intervention (PCI). Advancing technology has 
improved PCI outcomes overall but the impact of contemporary PCI among diabetics is 
unknown. Objective: To determine whether advances in technology and adjunctive phar- 
macology have affected short and long-term adverse outcomes in diabetics compared to 
non-diabetics. Methods: This analysis includes 4632 Dynamic Registry patients from 
two enrollment waves, t997-98 and 1999. Diabetes was defined as current use of either 
insulin or oral hypoglycamic agents; 1056 patients (23%) were classified as diabetic. 
Results: Compared to non-diabetics, diabetics were significantly (p<0.05) more likely to 
be female (47% vs 33%), non-white (31.5% vs 17%), to have a history of renal (8% vs 
3%) and pedpheral vascular disease (11% vs 6%), to have had a prior PCI (35% vs 27%) 
and CABG (22% vs 15%), to present with tdple vessel disease (32% vs 23%) and to 
have more total occlusions (41% vs 37%). Total angiographic success rates (94% vs 
93%) as well as angiographic omplication rates were similar between groups. In-hospi- 
tal mortality was increased in diabetics (2.3% vs 1.3%; p=0.O2), however after adjust- 
ment for important baseline factors, there was no significant difference for dsk of in- 
hospital mortality between groups (OR=1.46, 95% Confidence Interval (CI) 0.79-2.67). At 
1-year, diabetics had higher cumulative mortality (9.0% vs 4.1%, p<O.001) and risk of 
death remained higher following adjustment (RR=1.79, 95% CI 1.32-2.42). Diabetics also 
had a higher adjusted risk for the composite endpoint of death/MI/CABG at 1-year 
(RR=1.21, 95% CI 1.00-1.45). Conclusions: Despite having more clinical, procedural 
and angiographic risk factors, diabetics were at no greater risk of major in-hospital 
adverse events. Regardless of advances in PCI, diabetics were more likely to die or 
experience an adverse event during late follow-up. 
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844-2 Percutaneous Coronary Interventions in Diabetic 
Patients: The Impact of Complete Revasculerizetion on 
Long-Term Prognosis 
Evoenia Nikolskv, Chandreshekhar Patil, Ariel Roguin, Sirouch Petcherski, Michael 
Kapeliovich, Shai Linn, Monther Boulos, Ehud Grenadier, Walter Markiewicz, Rafael 
Beyar, Rambam Medical Center, Haifa, Israel, Rappaport Faculty of Medicine-Technion, 
Haifa, Israel. 
Background: Long-term prognosis of diabetic patients with multivessel coronary artery 
disease (CAD) treated with either surgical or percutaneous revasculadzation is signifi- 
cantly worse compared to non-diabetics. Lower rates of complete revasculadzation may 
be one of the factors of poor long-term outcome in diabetic population. The aim of our 
study was to assess the impact of complete revascularization (no residual stsnosis > 
50% in any major coronary artery or their large branches more than 1.5 mm in diameter) 
on long term prognosis in diabetic patients with CAD treated by psrcutaneous coronary 
interventions (PCI). 
Methods and Results: The study included 352 consecutive diabetic patients (mean age 
60.9±10.1 years) with multivessel CAD that were treated at our center from January 1, 
1992 to December 1, 1999. Revasculadzation was complete in 94 (26.7%) and incom- 
plete in 258 (73.3%) patients. The reasons for incomplete revascularization were small 
vessel size (1.5-2.5 mm), target vessel ravascularization strategy and chronic total occlu- 
sions. Procedural success was achieved in 96.4% of the cases. The rate of in-hospital 
major adverse cardiac events (MACE) was 1.7%. At mean follow-up of 3.1±1.7 years 
MACE were registered in 112 (31.8%) patients and included death (9.1%), myocardial 
infarction (MI) [3%] and repeat revassularizations (22.5%), most of them re-PCI (18.4%). 
The rates of 5- year survival and survival free from MI in the whole group were 87.4% 
and 84.5%, respectively, being significantly higher (p<0.001) in the arm with complete 
(94.5% and 92.9%) compared to group with incomplete revascularization (83% and 
79.9%). Muifivadate analysis identified age, female gender, left ventricle dysfunction, and 
incomplete revasculadzation as independent predictors of mortality (p=0.0O2; 0.025; 
0.0001 and 0.003, respectively), while left ventricle dysfunction and incomplete revascu- 
larization as predictors of total MACE at follow-up (p=O.002 and 0.004, respectively). 
Conclusions. Completeness of myocardial revascularization may have positive impact on 
Iong-tarm prognosis of diabetic patients with multivessel CAD treated with PCI. 
